GIMV NV (GIMB)
Euronext Brussels · Belgium · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 47.60 |
|---|---|
| 52-week range | 42.35 – 50.10 |
| Return, 1 month / 3 months | +0.5% / +6.1% |
| Return, 1 year / 3 years | +7.0% / +44.5% |
| Trend | Uptrend |
| RSI (14) | 62 |
| Volatility (1 year) | 18.4% |
| Worst drawdown (1 year) | -10.2% |
| Average daily value traded | 1.12M EUR |
| Dividend yield | 4.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
GIMV NV is an investment company based in Belgium that puts money into unlisted businesses, mainly small and medium-sized firms. It backs entrepreneurs and management teams through private equity, venture capital and growth investments, with a focus on sectors such as life sciences, technology and consumer goods. Its portfolio companies operate in Belgium and nearby European markets, and GIMV works with them as a long-term shareholder, helping them develop their activities and expand.
On this site GIMV NV appears as a stock on the Euronext Brussels (Belgium), code GIMB, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
GIMV NV (GIMB) trades on the Euronext Brussels in Belgium. It last closed at EUR 47.60 on 22 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 10 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 7.0% and over the last three months it rose 6.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 81 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 5.9% | ||
| From 52-week high | -4.2% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 6.1% | ||
| 6-month return | 2.3% | ||
| 12-month return, skipping the last month | 6.4% | ||
| Stability (higher is calmer) | 88 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 18.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -10.2% | ||
| Liquidity | 72 · Strong | Trades actively. | |
| Average daily value traded | 1.12M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 54 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.1% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +0.5% |
| 3 months | +6.1% |
| 6 months | +2.3% |
| 1 year | +7.0% |
| 3 years | +44.5% |
| 5 years | +11.4% |
Signals
| 50-day / 200-day average | 45.69 / 44.94 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.66 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 Jun 2026 | EUR 1.9500 |
| 30 Jun 2025 | EUR 2.6000 |
| 1 Jul 2024 | EUR 2.6000 |
| 3 Jul 2023 | EUR 2.6000 |
| 4 Jul 2022 | EUR 2.6000 |
| 5 Jul 2021 | EUR 2.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.